pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - agents antinéoplasiques - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
dexmedetomidine baxter 100 µg/ml sol. perf. (à diluer) i.v. flac.
baxter holding b.v. - chlorhydrate de dexmédétomidine 0,118 mg/ml - eq. dexmédétomidine 0,1 mg/ml - solution à diluer pour perfusion - 100 µg/ml - chlorhydrate de dexmédétomidine 0.118 mg/ml - dexmedetomidine
paracetamol baxter 10 mg/ml sol. perf. i.v. flac.
baxter holding b.v. - paracétamol 10 mg/ml - solution pour perfusion - 10 mg/ml - paracétamol 10 mg/ml - paracetamol
paracetamol baxter 10 mg/ml sol. perf. i.v. flac.
baxter holding b.v. - paracétamol 10 mg/ml - solution pour perfusion - 10 mg/ml - paracétamol 10 mg/ml - paracetamol
paracetamol baxter 10 mg/ml viaflo sol. perf. i.v.
baxter holding b.v. - paracétamol 10 mg/ml - solution pour perfusion - paracétamol 10 mg/ml - paracetamol
bortezomib baxter 3.5 mg sol. inj. (pdr.) s.c./i.v. flac.
baxter holding b.v. - bortézomib 3,5 mg - poudre pour solution injectable - 3,5 mg - bortézomib 3.5 mg - bortezomib
tranexamic acid baxter 100 mg/ml sol. inj./perf. i.v. flac.
baxter holding b.v. - acide tranexamique 500 mg/5 ml - solution injectable/pour perfusion - 100 mg/ml - acide tranexamique 100 mg/ml - tranexamic acid
tranexamic acid baxter 100 mg/ml sol. inj./perf. i.v. flac.
baxter holding b.v. - acide tranexamique 500 mg/5 ml - solution injectable/pour perfusion - 100 mg/ml - acide tranexamique 100 mg/ml - tranexamic acid
adenosine baxter 30 mg/10 ml, solution pour perfusion
baxter holding b.v. - adénosine - solution - 3 mg - composition pour 1 ml de solution injectable > adénosine : 3 mg - autres préparations cardiaques
adenosine baxter 6 mg/2 ml, solution injectable
baxter holding b.v. - adénosine - solution - 3 mg - composition pour 1 ml de solution injectable > adénosine : 3 mg - autres préparations cardiaques